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Abstract  
Osteoarthritis (OA) is a common degenerative joint disease, characterized by cartilage loss and 
subchondral bone remodelling in response to abnormal mechanical load. Heparan sulfate (HS) 
proteoglycans bind to many proteins that regulate cartilage homeostasis, including growth factors, 
morphogens, proteases, and their inhibitors, and modulate their localization, retention, and biological 
activity. Changes in HS expression and structure may thus have important consequences for joint 
health. We analyzed normal and osteoarthritic human knee cartilage, and found HS biosynthesis was 
markedly disrupted in OA, with 45% of the 38 genes analyzed differentially regulated in diseased 
cartilage. The expression of several HS core proteins, biosynthesis, and modification enzymes was 
increased in OA cartilage, whereas the expression of the HS proteoglycans syndecan 4 and betaglycan 
was reduced. The structure of HS was also altered, with increased levels of 6-O-sulfation in 
osteoarthritic samples, which correlated with increased expression of HS6ST1, a 6-O-sulfotransferase, 
and GLCE, an epimerase that promotes 6-O-sulfation. siRNA silencing of HS6ST1 expression in 
primary OA chondrocytes inhibited ERK phosphorylation in response to FGF2, showing that changes 
in 6-O-sulfation impact a key cartilage signalling pathway. Given the broad range of homeostatic and 
repair pathways that HS regulates, these changes in proteoglycan expression and HS structure are 
likely to have significant effects on joint health and progression of OA.  
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Introduction 
 
Osteoarthritis (OA) is a common degenerative joint disease in which articular cartilage loss and 
subchondral bone remodelling cause pain and impair movement of affected joints. There are currently 
no disease-modifying therapies available, and patients are largely treated with analgesia or joint 
replacement surgery. There is thus a substantial need to develop effective therapeutics that can slow 
or halt the progression of joint damage. 
The primary risk factors for development of OA are ageing and injury, which alter the mechanical 
environment of the joint and stimulate chondrocytes to produce catabolic proteinases that degrade the 
cartilage extracellular matrix. The pericellular matrix immediately adjacent to chondrocytes is thought 
to play a central role in transducing mechanical stimuli to biochemical signals within the cells.1 For 
example, loading of cartilage causes release of fibroblast growth factor 2 (FGF2) from the pericellular 
matrix, and activates downstream extracellular signal–regulated kinase (ERK) signalling pathways in 
chondrocytes.2, 3 FGF2 is localized in the pericellular matrix through its interaction with the heparan 
sulfate (HS) chains of perlecan,2 the major HS proteoglycan in cartilage. Pericellular matrix and cell 
surface HS also binds to a large number of other bioactive proteins, including growth factors [eg, 
connective tissue growth factor (CTGF) and transforming growth factor β (TGFβ)], morphogens [eg, 
bone morphogenetic protein (BMP)-4 and  BMP-7], proteinases [eg, matrix metalloproteinase 13 
(MMP-13), adamalysin with thrombospondin motifs 4 (ADAMTS-4), and ADAMTS-5], and 
proteinase inhibitors (eg, tissue inhibitor of metalloproteinases, TIMP-3), and regulates their 
retention, localization, and biological activity.4, 5 HS is thus a critical regulator of chondrocyte 
homeostasis and cartilage health. Previous studies have shown increased expression of some of the 
HS core proteins in OA, including perlecan,6-9 syndecan 19-11,  and syndecan 4,11-13  but nothing is yet 
known about how the structure of HS itself or its interactions with ligands changes in OA.  
HS interacts with proteins through electrostatic interactions between its negatively charged sulfate 
groups and positively charged lysine and arginine residues on the protein ligand. The number and 
arrangement of sulfate groups along the HS glycosaminoglycan chain determines the affinity of HS 
for its protein ligands and its ability to modulate their biological activity.14-16 This sulfation pattern is 
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generated by the template-independent action of a series of sulfotransferases during HS synthesis in 
the Golgi apparatus.17 The EXT family of glycosyltransferases initiate HS synthesis by adding 
sequential glucuronic acid (GlcA) and N-acetyl glucosamine (GlcNAc) residues to a linker 
tetrasaccharide attached to the core protein. GlcA can subsequently be epimerized to iduronic acid 
(IdoA) by glucuronyl C5-epimerase (GLCE).  The growing HS chain can then be N-sulfated on 
GlcNAc residues [by the N-deacetylase/N-sulfotransferases (NDSTs)], and/or O-sulfated on GlcNAc 
[by the 6-O-sulfotransferases (HS6STs) and 3-O-sulfotransferases (HS3ST)] and GlcA/IdoA [by the 
2-O-sulfotransferase (HS2ST1)].17 HS can also be edited in the extracellular environment by SULF1 
and SULF2 that remove 6-O-sulfate groups, or degraded by the heparanases HSPE1 and HSPE2. 
These reactions do not always occur to completion, generating a highly variable sulfation pattern that 
gives HS a structural complexity several orders of magnitude larger than the proteome. Temporal and 
spatial changes in HS sulfation occur during development18-21 and in diseases such as Alzheimer 
disease22, 23, cancer,24 diabetes,25 and fibrosis,26 and are thought to enable HS to coordinately regulate 
the retention and activity of multiple bioactive ligands, and thus to powerfully regulate tissue 
homeostasis. 
Here, we isolated RNA from knee cartilage of normal and osteoarthritic donors, and profiled 
expression of the 13 core proteins and 25 biosynthesis and modifying enzymes that govern HS 
structure and sulfation. Notably, disaccharide composition was examined by isolating HS from normal 
and OA cartilage. HS enzyme expression and glycan structure were found to be markedly 
dysregulated in OA cartilage, and increased 6-O-sulfation of HS was identified as the primary 
structural change associated with impaired cartilage homeostasis.   
 
Materials and Methods 
 
Human cartilage samples 
 
Human articular cartilage was obtained in full compliance with national and institutional ethical 
requirements, the United Kingdom Human Tissue Act, and the Declaration of Helsinki.  
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Normal human knee cartilage specimens used for RNA and glycosaminoglycan analyses were 
obtained from Articular Engineering LLC (Northbrook, IL) from donors (six females of 44 to 68 
years of age, six males of 32 to 75 years of age) with clinically healthy, normal cartilage and no 
history of OA, following informed donor consent and approval by local ethics committees and the 
University of Oxford Research Ethics Committee (R45926/RE001). Cartilage was aseptically 
harvested within 48 hours of death, flash frozen in liquid nitrogen, stored at -80 oC, and shipped in dry 
ice. 
Normal human knee cartilage specimens used for immunohistochemistry were obtained from 
Stanmore Biobank (Royal National Orthopaedic Hospital, Stanmore) from donors undergoing 
amputation for low limb malignancies with no involvement of the cartilage, following informed donor 
consent and approval by the Royal Veterinary College Ethics and Welfare Committee (Institutional 
approval Unique Reference Number 2012 0048H). Cartilage was aseptically harvested from all 
surfaces of the joint within four hours of surgery and processed for downstream analyses. 
Human OA cartilage samples used for immunohistochemistry, RNA, and glycosaminoglycan 
analyses were obtained from the Oxford Musculoskeletal Biobank from donors (six females of 58 to 
83 years of age, six males of 52 to 84 years of age) undergoing total knee replacement surgery for 
advanced OA, following informed consent and approval by the Oxford Research Ethics Committee C 
(09/H0606/11). Cartilage was aseptically harvested from all surfaces of the joint within four hours of 
surgery and processed for downstream analyses. 
 
RNA isolation 
 
Cartilage (300 mg) from 12 normal and 12 OA donors was ground under liquid nitrogen with a pestle 
and mortar. The ground cartilage powder was added to 1.5 mL of RLT lysis buffer supplemented with 
10 µL/mL β-mercaptoethanol (QIAGEN, UK), digested with proteinase K (6-10 mAU/100 mg of 
cartilage, 10 min at 55 °C, QIAGEN, UK) and transferred to an RNeasy micro column (QIAGEN, 
UK). RNA was extracted according to the manufacturers’ protocol with an intermediate DNA 
digestion step. The eluted RNA was quantified on a Nanodrop spectrophotometer and examined on a 
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Bioanalyser (Agilent, UK). RNA from healthy and OA cartilage had comparable RINs (6-7.7) and 
RNA yields.  
 
Reverse transcription and quantitative PCR 
 
Total RNA (250 ng) was reverse transcribed to cDNA using a reverse transcription kit 
(ThermoFisher) and cDNA amplified on a Taqman low density array (Table 1). Fold changes against 
the control samples were calculated using the ∆∆Ct method. For calculating the ∆Ct, the average of 
the three normalizing genes (18S, RLPL0, and GAPDH) was used. 
 
Extraction of HSPGs and disaccharide analysis 
 
Approximately 300 mg of frozen cartilage explants were ground in a pestle and mortar under liquid 
nitrogen and the powder was placed in 1 mL of Trizol (ThermoFisher Scientific, UK). After phase 
separation with the addition of chloroform, the aqueous phase was added to equilibrated DEAE-
Sephacel beads, washed with PBS and 0.25 M NaCl before elution with 2 M NaCl. The eluate was 
desalted on PD10 columns and freeze dried. The samples were then treated with DNase (QIAGEN, 
UK) and RNase, prior to incubation with chondroitinase ABC (Sigma Aldrich, UK), neuraminidase, 
keratanase, and pronase. Following the digestions, the samples were once more purified on DEAE 
beads and freeze dried. The rest of the procedure was as described before.27 Briefly, samples were 
sequentially digested with heparanase I, II, and III (IBEX Technologies, UK), purified on C18 and 
graphite spin columns (ThermoFisher Scientific, UK) and labelled with BIODIPY hydrazine 
(ThermoFisher Scientific, UK) as previously described.28 Finally, samples underwent ethanol 
precipitation to remove any copurified impurities. Samples were then analyzed by SAX HPLC using a 
Propac PA-1 strong anion-exchange column (4.6x250nm; Dionex, UK). Samples were eluted with a 
linear gradient of 0 to -1 M sodium chloride and isocratic sodium hydroxide (150 mM) over 30 min at 
1 mL/min on a Shimadzu HPLC system. An inline fluorimeter was used to detect eluted peaks 
(excitation λ = 488 nm, emission λ = 520 nm). Previously calculated correction factors were applied 
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to quantitate the observed disaccharides.27  
 
Immunofluorescence staining analysis 
 
Upon receipt, cartilage explants were embedded in OCT (Thermofisher Scientific, UK) and frozen in 
isopentane for storage at -80 °C until sectioning. Samples were mounted on a cryostat (CM1860UV, 
Leica, Milton Keynes, UK) and 5 µm sections were cut and mounted on Superfrost Plus microscope 
slides (ThermoFisher Scientific, UK) and stored at -80 °C. Frozen sections were air dried for one hour 
at room temperature and fixed with neutral buffered formalin for 5 minutes at room temperature prior 
to their incubation in ice cold acetone for 10 minutes at -20 °C, and incubated at 37 °C for 30 minutes 
with 0.1 U chondroitinase ABC (Sigma, C3667) in 1x chondroitinase buffer (40 mM Tris-acetate, pH 
8). The digested sections were blocked in 1% goat serum and 5% BSA in PBS for one hour at room 
temperature. After 15 minutes permeabilization with 0.1% Triton X-100 in PBS, sections were 
washed in PBS and the primary antibodies were applied diluted in block buffer overnight at 4 °C, or 
isotype antibodies as negative controls. The following antibodies were used: rat anti-perlecan 
(HSPG2) (1:1000, Millipore, UK), rabbit anti-GLCE (1:20, HPA04821, Atlas Antibodies, Sweden), 
rabbit anti-EXTL2 (1:100, NBP2-16394, Novus, UK), mouse anti-NDST1 (3 µg/mL, ab55296, 
Abcam, UK), rabbit anti-GPC1 (1:250, HPA303571, Sigma, UK) and rabbit anti-HS6ST1 (1:250, 
ab106195, Abcam, UK). After washing in PBS at room temperature, the appropriate secondary 
antibodies were added; either in combination, or in unison, goat anti-rat Alexa Fluor 488 (1:1000, 
Thermo Fisher Scientific, UK), goat anti-rabbit Alexa Fluor 568 (1:500, Thermo Fisher Scientific, 
UK), or goat anti-mouse Alexa Fluor 568 (1:500, Thermo Fisher Scientific, UK) in block buffer. The 
secondary antibodies were washed off with PBS after three hours at room temperature. Nuclei were 
stained with DAPI (1:200 in PBS, Thermo Fisher Scientific, UK) for one hour before a final wash in 
PBS and mounting in Prolong  Diamond antifade (Thermo Fisher Scientific UK).  
Sections were viewed under an Olympus BX51 fluorescent microscope (Olympus, UK). For each 
protein the optimal duration of exposure was determined as that giving a signal in positively stained 
sections and no detectable staining in negatively stained sections, and avoiding overexposure and 
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signal saturation. The exposures used were: HSPG2 200-250 ms, EXTL2 125 ms, GLCE 200 ms, 
GPC1 125 ms, NDST1 280-300 ms, and HS6ST1 275-300ms. Images were obtained from at least six 
random regions of the cartilage under a 40x lens and then analyzed on ImageJ as described 
previously.29, 30 For representative images, the intensity of the red and green signal was adjusted for 
illustrative purposes. For quantification, raw unaltered images were analyzed. 
 
Analysis of ERK phosphorylation in chondrocytes 
 
Primary OA chondrocytes were isolated from freshly harvested human OA cartilage by chopping the 
tissue finely and incubating in DMEM with 10% fetal calf serum (Gibco/ThermoFisher Scientific, 
UK) and 1.5 mg/mL type II collagenase (Roche, Switzerland) (18 hours,  37 °C, with shaking at 180 
rpm). The suspension was passed through a cell strainer, pelleted, and washed twice with medium. 
Isolated chondrocytes were cultured for seven days until confluent31 and stored at -80 °C until 
required. For small interfering RNA (siRNA) transfection, chondrocytes (3x105/well) were 
transfected with 20 nM of either Silencer Select Negative control #1 or Silencer Select HS6ST1 
siRNA (s17978, Ambion/ThermoFisher Scientific, UK) using Lipofectamine 2000 
(Gibco/ThermoFisher Scientific, UK) in serum free Opti-MEM I (ThermoFisher Scientific).31 After 
four hours, the medium was replaced with DMEM containing 10% FCS and cell cultured for a further 
72 hours.  
To analyze ERK phosphorylation, siRNA-treated chondrocytes were cultured in serum-free 
DMEM for 24 hours, and treated with PBS recombinant human FGF2 (R&D Systems, USA) (20 ng/ 
mL, 10 min). Cells were then washed twice with ice-cold PBS and lyzed on ice in 150 µL RIPA 
buffer containing protease inhibitors (SIGMAFAST, Sigma-Aldrich, UK) and phosphatase inhibitors 
(20mM NaF, 100 mM Na3VO4, 100 mM beta-glycerophosphate, 100 mM sodium pyrophosphate). 
Lysates were centrifuged (5000 rpm, 3 min) and 20 µg of protein analyzed by immunoblotting using 
antibodies against phosphoERK1/2 (1:2500, E7028, Sigma-Aldrich, UK) and total ERK (1:5000, 
4695S, Cell Signalling Technology, UK) in block buffer (5% milk/PBST). After 3x 5 min washes 
with PBST, the membranes were incubated with an AP-conjugated anti-rabbit secondary antibody 
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(1:2000,  Promega, UK) and developed using Western Blue stabilized substrate (Promega, UK). 
Immunoblots were analyzed by densitometry using Phoretix 1D software (TotalLab, Newcastle-upon-
Tyne, UK) and the levels of phospho-ERK normalized to total ERK for each treatment, and expressed 
relative to the corresponding untreated sample (defined as 1). 
Efficacy of siRNA silencing was confirmed by isolating RNA from RIPA lysates (20 to 50 µL, 
diluted to 350 µL with RLT buffer containing 1% v/v β-mercaptoethanol) using RNeasy micro kits 
according to the manufacturer’s protocol (QIAGEN, Germany). Isolated RNA was reverse transcribed 
and expression of 18S, GAPDH, and HS6ST1 quantified as described above.  
 
Statistical analysis 
 
All statistical tests, except correlations and linear regression models, were performed in Graphpad 
Prism version 7.0d. All other statistical tests were performed in R. All significant changes are 
annotated in the figures. 
Power calculations were based on pilot data from four samples per group. According to the pilot 
experiments, the sample size required for a two-tailed t-test was calculated with an effect size of 1.5 
(difference between means of 0.6 and standard deviation of 0.4) and type I error rate α at 5%, to be 12 
samples per group. Therefore the groups were extended to the appropriate sizes. 
Prior to performing any parametric test, groups were tested for normality using the D’Agostino 
and Pearson omnibus test.32  
Two-way ANOVA was performed and the forest plots (Figure 1) examined to evaluate whether 
there was significant variation in the age or sex of the donors.  
All tests on the PCR results were performed on the ∆∆Ct values as they were normally distributed. 
Multiple two-tailed t-tests were performed, comparing the expression of each gene between the two 
groups. The derived P-values were corrected for multiplicity using the two-stage step-up method of 
Benjamini, Krieger and Yekutieli (BKY), with a false discovery rate cut-off at 5%.33 
For HS disaccharide composition, site of sulfation and extent of sulfation, two-way ANOVA was 
performed, with a BKY multiplicity correction. 
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Hierarchical clustering was performed in R (https://www.r-project.org) using the package gplots 
ß and RColorBrewer. Canberra distance was employed as the clustering metric. 
For analysis of immunofluorescence images, the background-corrected integrated intensity values 
per cell were aggregated for the normal and OA groups (n = 3 to 6 per group), and the cumulative 
distributions of signal were analyzed using the Kolmogorov-Smirnov test, since the values were not 
normally distributed.  
 
Results 
 
Expression of HS proteoglycan core proteins is disrupted in OA cartilage 
 
RNA was isolated from normal and osteoarthritic tibial knee cartilage (n = 12 per group), and 
examined expression of 13 genes encoding HS proteoglycan core proteins. Genes with a significant 
change in expression are shown in Figure 1.  
Expression of agrin (AGRN) and perlecan (HSPG2) was significantly increased in OA samples 
(multiple t-tests, BKY corrected q>0.05), whereas expression of betaglycan (TGF β receptor III, 
TGFBR3) was reduced.  
Among the syndecan family, syndecan 2 (SDC2) was not differentially regulated between the 
groups, whereas expression of syndecan 4 (SDC4) was reduced in OA, and expression of syndecan 1 
(SDC1) and syndecan 3 (SDC3) was increased. SDC1 was the most strongly regulated of the HS core 
proteins, with mean expression increasing 17-fold in OA.   
Glypican core proteins showed fewer changes in expression in OA cartilage, with only glypican 1 
(GPC1) showing significantly higher expression in OA samples. Expression of glypican 4 (GPC4), 
glypican 5 (GPC5), and glypican 6 (GPC6) was not significantly regulated, and glypican 2 (GPC2) 
and glypican 3 (GPC3) were minimally expressed in both normal and OA cartilage.  
 
Expression of HS biosynthesis and modifying enzymes was also disrupted in OA cartilage 
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Using the same samples, expression of 25 genes encoding HS biosynthesis and modifying enzymes 
was analyzed (Figure 1), and 10 of these were found to be expressed at higher levels in OA cartilage.  
Expression of EXT1 and EXT2, which extend the growing HS chain, was increased in OA, as was 
expression of the related EXTL1 and EXTL2 genes. EXTL1 was the most strongly regulated of all the 
genes examined, showing a 24-fold increase in expression in OA. Expression of EXLT3 was not 
significantly regulated. Mean expression of epimerase (GLCE), which epimerizes glucuronic acid 
(GluA) to iduronic acid (IdoA), was increased 2-fold in OA cartilage.  
Mean expression of the N-sulfotransferase NDST1 was 3-fold higher in OA cartilage.  NDST2 was 
expressed at similar levels in both sample groups, and NDST3 and NDST4 were not appreciably 
expressed in either normal or OA cartilage.  
Expression of the 2-O-sulfotransferase HS2ST1 was not significantly altered in OA samples. Of 
the seven isoforms of 3-O-sulfotransferase, only HS3ST1 showed increased expression in OA 
cartilage, with expression of HS3ST3A1 and HS3ST3B1 not differentially regulated and four of the 
isoforms (HS3ST2, HS3ST3, HS3ST5, HS3ST6) not detectably expressed in cartilage. Among the 
three 6-O-sulfotransferases isoforms, expression of HS6ST1 was increased in OA cartilage, whereas 
HS6ST3 expression was similar in both sample groups and HS6ST2 was expressed at low levels.  
Expression of both SULF1 and SULF2 was increased in OA cartilage, with HSPE and HSPE2 not 
differentially expressed.  
Cluster analysis of the samples, based on the levels of the significantly regulated genes, separated 
the samples into two clusters (Figure 2), with the first cluster containing all the OA samples and one 
of the normal samples, and the second cluster containing the remaining normal samples. This 
indicates that levels of expression of the 17 significantly regulated genes are largely able to 
discriminate normal and osteoarthritic cartilage.  
 
Selected immunohistochemical analyses validate observed changes in expression 
 
To establish whether the observed gene regulation  resulted in corresponding changes in protein 
expression, six proteins (HSPG2, EXTL2, GLCE, NDST1, HS6ST1 and GPC1) were selected to 
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analyze by semi-quantitative immunofluorescence staining on frozen sections of normal and OA 
cartilage. HSPG2 was selected as a marker of pericellular matrix localization, and the other five 
proteins according to functional antibody availability and to have at least one from each category of 
HS core proteins and biosynthetic enzymes. The intensity of staining did not vary with cartilage depth 
for any of the antibodies examined. 
As expected, HSPG2 exhibited a predominantly pericellular localization,34 with approximately 
50% increased expression per cell in the four OA samples examined compared to the six normal 
cartilage samples.   
EXTL2 had a predominantly perinuclear localization in both normal and OA cartilage (Figure 
3A). In OA cartilage, expression of EXTL2 was increased 1.6-fold, with a decrease in the number of 
cells not expressing EXTL2 and a shift towards more cells expressing moderate amounts of the 
protein (Figure 3B). 
GLCE was similarly localized in the perinuclear region of cells (Figure 3C), with 2.4-fold higher 
expression in OA and a shift towards more cells expressing modest amount of the enzyme (Figure 
3D). 
HS6ST1 intensity levels were approximately three times higher in OA (Figure 4B). The protein 
appeared to be expressed at low levels around the nucleus in normal cartilage and to show some 
pericellular staining in the OA samples (Figure 4A). 
NDST1 was localized in the perinuclear region in normal cells, with more expression towards the 
periphery of the cell and overlapping with HSPG2 in the OA samples (Figure 4C). Intensity levels 
were approximately 3.6-fold higher in the OA samples (Figure 4D).  
Staining for GPC1 was predominantly intracellular (Figure 5A), with 5.5-fold higher intensity in 
OA samples (Figure 5B). 
 
Increased 6-O-sulfation of HS in OA cartilage 
 
The amount and disaccharide composition of HS isolated from normal and OA cartilage was analyzed 
(n = 8 per group, Figure 6A).  
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There was no significant difference in the total amount of HS in the normal and OA cartilage 
samples (5.7 ± 2.3 µg/100 mg in the normal samples, 3.0 ± µg/100 mg of tissue in OA, P >0.05 by t-
test, Figure 6B), or in the ratio of sulfated to total HS disaccharides (36.5 % in normal cartilage, 53% 
in OA cartilage, Mann Whitney test, P > 0.05, Figure 6C).  
Normal and OA cartilage did not differ significantly in the abundance of any single HS 
disaccharide (Figure 6D), or in the percentages of non-, mono-, di-, or triple-sulfated disaccharides 
(not shown). However, the percentage of 6-O-sulfated disaccharides was increased in OA cartilage 
(19.8% vs 12.1%, Mann Whitney test, P = 0.0379, Figure 6E). 
 
6-O-sulfation of HS correlates with expression of GLCE, HS6ST1, EXTL2, and HS3ST3A1 
 
It was examined whether expression of any of HS biosynthesis genes correlated with the HS 
disaccharide compositions quantified.  
The percentage of 6-O-sulfated disaccharides correlated with expression of HS6ST1 (r = 0.74, P = 
0.0016, Figure 6F), GLCE (r = 0.775, P = 0.0007, Figure 6G), EXTL2 (r = 0.57, P = 0.026), and 
HS3ST3A1 (r = 0.575, P = 0.025).  The relationship between 6-O-sulfation and HS6ST1 expression 
was linear, with a 4% increase in abundance of 6-O-sulfated disaccharides for every doubling in the 
amount of HS6ST1 (adjusted R2 = 0.525, P = 0.0014). This relationship was independent of age, OA, 
and sex. The relationship between 6-O-sulfation and GLCE expression was linear, with a doubling in 
expression of GLCE increasing the percentage of 6-O-sulfation by about 4%. This relationship was 
dependent on age and sex, such that for every year increase in age there was a 0.17% increase in 
percent 6-O-sulfation, and that females had about 4% more 6-O-sulfation for the same amount of 
GLCE (adjusted R2 = 0.42, P = 0.028).  
The percentage of 2-O-sulfated disaccharides correlated with expression of HS3ST3A1 (r = 0.796, 
P = 0.0004) and HS6ST1 (r = 0.57, P = 0.026). The relationship between 2-O-sulfation and 
HS3ST3A1 expression was linear, with a doubling in the levels of HS3ST3A1 increasing the 
percentage of 2-O-sulfated disaccharides by 4%. This association was OA- and sex-dependent, such 
that females with OA had a 0.62% increase in 2-O-sulfation for the same level of 
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HS3ST3A1expression (adj R2 = 0.67, P = 0.0036). 
Correlations were also examined between expression of HS biosynthesis genes and the relative 
abundance of individual disaccharide residues. This showed that HS3ST3A1 expression correlated 
with the percentage of UA(2S)-GlcNAc (r = 0.772, P < 0.05), UA(2S)-GlcNS (r = 0.538, P < 0.05), 
and UA-GlcNS(6S) (r = 0.521, P < 0.05), whereas HS6ST1 expression correlated with the percentage 
of UA(2S)-GlcNAc (r = 0.53, P < 0.05), UA-GlcNAc(6S) (r = 0.58, P < 0.05), and UA-GlcNAc (r = -
0.686, P = 0.005).  
Finally, HS3ST2 expression was found to be linearly associated with age, independent of OA and 
sex, with expression of HS3ST2 increasing by 6% to 21% every year (adj R2 =0.341, P = 0.035). 
 
siRNA silencing of HS6ST1 inhibits FGF2 signalling  
 
To  investigate whether changes in HS6ST1 expression and 6-O-sulfation have the capacity to 
alter signalling in OA chondrocytes, chondrocytes were isolated from knee cartilage of five donors 
with late-stage OA, and FGF2-dependent ERK phosphorylation examined after siRNA knockdown of 
HS6ST1. siRNA treatment suppressed HS6ST1 mRNA levels by >90% in all five donors (Figure 6H). 
Addition of 20 ng/mL FGF-2 stimulated rapid phosphorylation of ERK, and this was significantly 
reduced (by 40%) in HS6ST1-silenced cells (Figure 6I).   
 
Discussion 
 
HS proteoglycans control the retention, localization, and biological activity of over 400 bioactive 
molecules, including growth factors (eg, FGF2, TGFβ), morphogens (eg, BMP-4, BMP-7), 
proteinases (eg, MMP-13, ADAMTS-4, ADAMTS-5), and proteinase inhibitors (eg, TIMP-3).4, 35-37 
Many HS ligands have significant impacts on cartilage homeostasis, making HS a critical regulator of 
joint health. Despite this important role, nothing was previously known about how the structure and 
sulfation pattern of HS may change during the development of osteoarthritis. This study shows that 
the expression of HS biosynthesis and modifying enzymes and the resulting HS disaccharide 
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composition differs significantly in normal and osteoarthritic human knee cartilage.  
Expression of the HS polymerases EXT1 and EXT2, as well as EXTL1 and EXTL2, was 
significantly increased in OA cartilage. The roles of these enzymes in homeostasis of adult cartilage 
has not been explored, but EXT1 and EXT2 are known to be important in musculoskeletal 
development. EXT1 regulates Ihh signalling during endochondral ossification,38 and mutations in both 
EXT1 and EXT2 are associated with development of hereditary multiple exostoses, an inherited 
pediatric disorder characterized by osteochondroma formation.39 Aberrant activation of chondrocyte 
hypertrophy has been implicated in development of OA,40 and may underlie the elevated expression 
of EXT1 and EXT2 observed. The role of the related EXTL genes in HS synthesis are less well 
understood, but they are thought to regulate early stages of HS chain elongation.41 Mutations in 
EXTL3 have been shown to impair musculoskeletal development,42 and although EXTL3 expression 
was not regulated in OA, expression of both EXTL1 and EXTL2 was strongly up-regulated.  
Once polymerized, the HS chain can be modified by epimerization of GlcA to IdoA by a 
glucuronyl epimerase (GLCE), or by addition of sulfate groups to specific positions in the 
disaccharide units, by multiple sulfotransferases. The expression of 11 human HS sulfotransferases 
was measured and it was found that the expression of NDST1, HS3ST1, and HS6ST1 was elevated in 
OA cartilage. Most notably, a significant increase was observed in the level of 6-O-sulfated 
disaccharides in OA cartilage, which correlated strongly with expression of both HS6ST1 and GLCE. 
Epimerization of GlcA to IdoA by GLCE is thought to favor subsequent 6-O-sulfation,43 suggesting 
that these two enzymes drive the increase in 6-O-sulfation in OA cartilage. Previous studies have 
shown that levels of 6-O-sulfation are spatially and temporally regulated during development,18, 19, 21 
and in diseases such as fibrosis,44, 45 Alzheimer disease,22 and cancer.46, 47 In the case of fibrosis, a 
doubling in 6-O-sulfation is thought to exacerbate disease by amplifying TGFβ44 and FGF-245 
signaling. We hypothesized that increased 6-O-sulfation in OA cartilage may similarly amplify 
downstream signalling pathways and alter tissue homeostasis. Consistent with this, using primary OA 
chondrocytes isolated from five different donors, it was found that siRNA silencing of HS6ST1 
suppressed ERK phosphorylation in response to FGF2. This is in line with previous studies showing 
that 6-O-sulfation of HS promotes FGF2 signalling,48-51 and confirms that changes in 6-O-sulfation 
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can alter biologically relevant signalling pathways in cartilage. 6-O-sulfation is known to alter HS 
affinity for a range of ligands,52 with varying effects on their downstream activity. For example, 6-O-
sulfation promotes TGFβ53, 54 signalling, and inhibits Wnt55, 56 and BMP57, 58 signalling. An unbiased 
approach such as phosphoproteomics will be required to identify pathways regulated by 6-O-sulfation 
in normal and OA cartilage. 
The importance of 6-O-sulfation is underscored by the fact that it is the only HS modification that 
is regulated at both the ‘on’ and the ‘off’ level, being added during HS biosynthesis in the Golgi 
apparatus by HS6ST1, HS6ST2, and/or HS6ST343, and removed in the extracellular environment by 
the 6-O-endosulfatases SULF1 and/or SULF2.59 This permits “remodelling” of HS sulfation that is 
apparently critical to regulation of its functions. Indeed, increased expression of SULF1 and SULF2 
was observed in OA cartilage, in line with previous reports examining both human and murine OA 
cartilage.7, 9, 11, 58, 60, 61 Despite this, net levels of 6-O-sulfation were increased in our OA cartilage 
samples. As noted in recent studies from HS in muscle,27 this highlights the importance of analysing 
HS structure directly, and may indicate post-translational regulation of HS6ST and/or SULF activity, 
or differences in the catalytic efficiency, location, or stability of the enzymes.  Sulf1-/- and Sulf2-/- mice 
developed accelerated OA and injection of recombinant SULF1 into the joint reduced cartilage 
damage,62 indicating the enzymes play a chondroprotective role. Elevated 6-O-sulfation may 
contribute to or perpetuate cartilage damage, potentially through driving anabolic pathways or 
impairing catabolic repair mechanisms.  
No increase was seen in N-sulfation in OA cartilage, despite increased expression of NDST1 at the 
mRNA and protein level. The abundance of 3-O-sulfated disaccharides was not quantified due to their 
relative scarcity, but expression of HS3ST1 was elevated in OA samples. Further investigation may be 
warranted as knowledge of the functional impact of 3-O-sulfation and the extent of the 3-O-proteome 
expands.63, 64   
With regards to the HS core proteins the previously reported increase in expression of HSPG26-9, 
glypican 1,11 syndecan 19-11, and syndecan 365 was observed in OA cartilage, but not the previously 
observed increase in syndecan 49, 11-13  or decrease in agrin.66 This may suggest species- or joint-
specific variation in expression of these genes. Additionally, the expression of many HS-associated 
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genes was significantly altered by isolation and culture of chondrocytes (data not shown), suggesting 
that HS biosynthesis is dynamically regulated by the chondrocyte microenvironment and that 
expression may change during the course of OA development. 
A significant reduction was observed in the expression of TGFBR3 in OA cartilage. This HS core 
protein, also known as beta-glycan, does not have the ability to signal directly, but promotes TGFβ 
signalling by recruiting the growth factor and presenting it to the type II TGFβ receptor. In 
chondrocytes, TGFBR3 was recently shown to promote activation of latent TGFβ in a CTGF- and 
HS-dependent manner.67 Reduction in expression of TGFBR3 in OA is thus likely to impair the 
chondroprotective effects of TGFβ signalling.  
Previous rodent microarray studies indicate that expression of some HS core proteins, 
biosynthesis, and modifying enzymes is regulated early in the course of OA development.7, 8, 11, 68-72 
For example, expression of Ext1,11, 68 Sdc1, 11, 68, 69 Gpc1, 11, 69 and Hspg211, 68 is significantly 
increased within two to four weeks of surgical OA induction (Supplementary Table S170-72), in line 
with our findings here. Data on early changes in expression of sulfotransferases are variable, and early 
changes in Hs6st1 were not reported. This may suggest that expression of this gene is stimulated once 
cartilage damage starts to escalate, but may also reflect differences between rodent post-traumatic OA 
and more variable human disease.  
Age is a primary risk factor for the development of OA, and it is important to understand the 
cellular mechanisms that increase risk with age if we are to develop effective therapies to treat the 
disease. Previous studies have shown that HS sulfation patterns change with age in various tissues, 
including the aorta,73 myocardium,74 muscle stem cell niche27, and brain,75, 76 with concomitant 
changes in growth factor signalling. Although this study was not powered to detect changes in HS 
disaccharide composition with age, the expression of HS3ST2 in cartilage was found to increase with 
age, in contrast to what has previously been reported in skin.77 However, this observation is based on 
a low number of individuals (n = 11) as some values were missing for HS3ST2 expression. Further 
analysis of age-dependent changes in HS structure may identify changes that impair cartilage repair 
with age and so increase the risk of OA after injury.  
Our analysis identified 6-O-sulfation as the primary HS motif that is altered in end-stage OA 
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cartilage, validating it as a new target for potential therapeutic interventions. To understand the impact 
this change has on cartilage repair and OA progression, it will be necessary to perform unbiased 
analyses of the 6-O-sulfate-binding proteome in normal and OA cartilage. Comparative mass 
spectrometry approaches have proved useful in examining the 3-O-sulfate-binding proteome in 
cultured cells,64 and similar methods could be developed for cartilage analysis. Analysis of other joint 
tissues (eg, bone, synovium, meniscus) and earlier stages of OA progression can also be expected to 
shed further light on the role of HS in adult joint homeostasis.    
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Figure legends  
 
Figure 1.  Changes in heparan sulfate (HS)-related gene expression in human osteoarthritis (OA)  
cartilage. Expression of HS-associated genes in normal and OA cartilage (n = 12 per group) was 
analyzed using Taqman low-density arrays. Fold changes in expression were determined by the ∆∆Ct 
method against the average of the normal samples. A: Fold changes in expression of HS core protein 
genes. B: Fold changes in expression of HS chain elongation and sulfatase genes. C: Fold changes in 
expression of sulfotransferase genes. Error bars represent 95% of confidence intervals of the mean. 
**q <0.01, ***q < 0.001, ****q < 0.0001 by BKY corrected multiple t-test.  
 
Figure 2.  Expression of heparan sulfate (HS)-associated genes is altered in osteoarthritis (OA) 
cartilage. A: Forest plot showing there is no significant difference between the ages and sexes of 
normal (n = 12) and OA (n = 12) cartilage donors used for gene expression analysis. M, male; F, 
female. Bars show 95% confidence intervals of the mean, dotted line shows Y=0. B: Expression of 
HS-associated genes in normal and OA cartilage was analyzed using Taqman low-density arrays. Fold 
change in expression were determined by the ∆∆Ct method against the average of the normal 
samples. The heatmap shows only those HS-associated genes whose expression was significantly 
different in the two groups (n = 12 for each group; BKY corrected multiple t-test; q-value < 0.05), 
with increased expression in OA shown in red, reduced expression shown in blue, and no change 
indicated in green. Cluster analysis based on the expression levels of significantly regulated genes 
separated the samples into two clusters, with the first cluster containing all of the OA samples and one 
of the normal samples, and the second cluster containing the remaining normal samples. 
 
Figure 3.  Expression of HSPG2, EXTL2, and GLCE is increased in human osteoarthritis (OA) 
cartilage. A: Representative images showing expression of HSPG2 and EXLT2 in human normal and 
OA cartilage. B: Expression of HSPG2 and EXLT2 was semi-quantitatively evaluated in three normal 
donors (N1, N2, and N3) and three OA donors (OA1, OA2, and OA3), with each dot representing 
integrated fluorescence intensity per single cell, calculated from at least six random fields of view on 
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three sections per donor. For each donor, the median fluorescence intensity with 95% confidence 
intervals of the mean are shown. C: Representative images showing expression of HSPG2 and GLCE 
in human normal and OA cartilage. D: Expression of HSPG2 and GLCE was semi-quantitatively 
evaluated in three normal donors (N4, N5 and N6) and three OA donors (OA1, OA2, and OA4) as 
described in B. **P < 0.01, ***P < 0.001, ****P < 0.0001 by Kolmogorov-Smirnov test. Scale bar = 
260 µm.  
 
Figure 4.  Expression of HSPG2, HS6ST1, and NDST1 is increased in human osteoarthritis (OA) 
cartilage. A: Representative images showing expression of HSPG2 and HS6ST1 in human normal and 
OA cartilage. B: Expression of HSPG2 and HS6ST1 was semi-quantitatively evaluated in three 
normal donors (N4, N5, and N6) and three OA donors (OA1, OA2, and OA4), with each dot 
representing integrated fluorescence intensity per cell, calculated from at least six random fields of 
view on three sections per donor. For each donor, the median fluorescence intensity with 95% 
confidence intervals of the mean are shown. C: Representative images showing expression of HSPG2 
and NDST1 in human normal and OA cartilage. D: Expression of HSPG2 and NDST1 was semi-
quantitatively evaluated in three normal donors (N1, N2, and N3) and three OA donors (OA1, OA2, 
and OA3) as described in B. *P < 0.05, ****P < 0.0001 by Kolmogorov-Smirnov test. Scale bar = 
260 µm. 
 
Figure 5.  Expression of HSPG2 and glypican 1 (GPC1) is increased in human osteoarthritis (OA) 
cartilage. A: Representative images showing expression of HSPG2 and GPC1 in human normal and 
OA cartilage. B: Expression of HSPG2 and GPC1 was semi-quantitatively evaluated in three normal 
donors (N1, N2, and N3) and three OA donors (OA1, OA2, and OA3), with each dot representing 
integrated fluorescence intensity per cell, calculated from at least six random fields of view on three 
sections per donor. For each donor, the median fluorescence intensity with 95% confidence intervals 
of the mean are shown.  **P < 0.01 by Kolmogorov-Smirnov test. Scale bar = 260 µm.  
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Figure 6.  6-O-sulfation is increases in osteoarthritis (OA) cartilage. Heparan sulfate (HS) was isolated 
from normal (n = 8) and OA (n = 8) cartilage and its composition analyzed by disaccharide analysis. 
A: Forest plot showing there is no significant difference between the ages and sexes of normal (n = 8) 
and OA (n = 8) cartilage donors used for HS analysis. M, male; F, female. Bars show 95% confidence 
intervals of the mean, dotted line shows Y=0. B: The total amount of HS in OA cartilage is not 
statistically different from that in normal cartilage. C: The ratio of sulfated to total HS is not 
statistically different between the two groups of samples. D: Abundance of individual disaccharide 
species is not significantly different in normal and OA cartilage. GlcNAc, N-acetyl glucosamine; 
GlcNS, N-sulfoglucosamine; UA, uronic acid; 2S,  2-O-sulfate; 6S, 6-O-sulfate. E: 6-O-sulfated HS 
disaccharides are more abundant in OA cartilage, whereas levels of N- and 2-O-sulfation are not 
significantly altered. F: The level of 6-O-sulfation in donor cartilage correlates with expression of 
HS6ST1 (n = 15, normal cartilage shown in black, OA cartilage in grey, males as squares, female 
samples as circles). G: The level of 6-O-sulfation in donor cartilage also correlates with expression of 
GLCE (n = 15, normal cartilage shown in black, OA cartilage in grey, males as squares, female 
samples as circles). H: Expression of HS6ST1 in primary OA chondrocytes is silenced using siRNA (n 
= 5  donors). NT, transfected with non-targeting siRNA. I: Silencing of HS6ST1 in primary OA 
chondrocytes reduces phosphorylation of ERK in response to FGF2 (20 ng/mL, 10 min) (n = 5 
donors).  *P < 0.05, **P <0.01, ***P < 0.001, multiple t-tests BKY corrected.  
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Table 1: Primer/probe sets used on custom-designed Taqman low density arrays. 
     
Gene name Primer/probe set 
Chain elongation 
EXT1 Hs00609162_m1 
EXT2 Hs00181158_m1 
EXTL1 Hs00184929_m1 
EXTL2 Hs01018237_m1 
EXTL3 Hs00918601_m1 
N-deacetylase/ N-sulfotransferases 
NDST1 Hs00925442_m1 
NDST2 Hs00234335_m1 
NDST3 Hs01128584_m1 
NDST4 Hs00224024_m1 
Glucuronyl C5-epimerase 
GLCE Hs00392011_m1 
2-O-sulfotransferase 
HS2ST1 Hs00202138_m1 
3-O-sulfotransferases 
HS3ST1 Hs00245421_s1 
HS3ST2 Hs00428644_m1 
HS3ST3A1 Hs00925624_s1 
HS3ST3B1 Hs00797512_s1 
HS3ST4 Hs00901124_s1 
HS3ST5 Hs00999394_m1 
HS3ST6 Hs03007244_m1 
6-O-sulfotransferases 
HS6ST1 Hs00757137_m1 
HS6ST2 Hs02925656_m1 
HS6ST3 Hs00542178_m1 
Editing enzymes 
HSPE Hs00935036_m1 
HSPE2 Hs00222435_m1 
SULF1 Hs00290918_m1 
SULF2 Hs01016476_m1 
Core proteins 
AGRN Hs00394748_m1 
GPC1 Hs00892476_m1 
GPC2 Hs00415099_m1 
GPC3 Hs01018936_m1 
GPC4 Hs00155059_m1 
GPC5 Hs00270114_m1 
GPC6 Hs00170677_m1 
HSPG2 Hs00194179_m1 
SDC1 Hs00896423_m1 
SDC2 Hs00299807_m1 
SDC3 Hs01568665_m1 
SDC4 Hs00161617_m1 
TGFBR3 Hs01114253_m1 
Normalizing genes 
18S Hs99999901_s1 
RPLP0 Hs99999902_m1 
GAPDH Hs99999905_m1 
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